Page 298 - Read Online

Fung et al. Antivirals in hepatitis B hepatocellular carcinoma

Ethics approval analog inhibitors of hepatitis B virus polymerase: mechanism of
Not applicable. action and resistance. Curr Opin Virol 2014:1-9.
19. Seifer M, Hamatake R, Colonno R, Standring D. In vitro inhibition of
hepadnavirus polymerases by the triphosphates of BMS-200475 and
REFERENCES lobucavir. Antimicrob Agents Chemother 1998;42:3200-8.
20. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM,
1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations Murad MH; American Association for the Study of Liver Disease.
of worldwide prevalence of chronic hepatitis B virus infection: a AASLD guidelines for treatment of chronic hepatitis B. Hepatology
systematic review of data published between 1965 and 2013. Lancet 2016;63:261-83.
2015;386:1546-55. 21. European Association for the Study of the Liver. EASL 2017 Clinical
2. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular Practice Guidelines on the management of hepatitis B virus infection.
carcinoma. Gastroenterology 2012;142:1264-73.e1. J Hepatol 2017;67:370-98.
3. Fung J, Lai CL, Yuen MF. Hepatitis B and C virus-related 22. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen
carcinogenesis. Clin Microbiol Infect 2009;15:964-70. DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL,
4. Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S,
hepatocellular carcinoma. J Hepatol 2016;64:S84-101. Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma
5. Sung WK, Zheng H, Li S, Chen R, Liu X, Li Y, Lee NP, Lee WH, BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-
Ariyaratne PN, Tennakoon C, Mulawadi FH, Wong KF, Liu AM, Pacific clinical practice guidelines on the management of hepatitis B:
Poon RT, Fan ST, Chan KL, Gong Z, Hu Y, Lin Z, Wang G, Zhang a 2015 update. Hepatol Int 2016;10:1-98.
Q, Barber TD, Chou WC, Aggarwal A, Hao K, Zhou W, Zhang C, 23. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee
Hardwick J, Buser C, Xu J, Kan Z, Dai H, Mao M, Reinhard C, Wang T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J.
J, Luk JM. Genome-wide survey of recurrent HBV integration in Lamivudine for patients with chronic hepatitis B and advanced liver
hepatocellular carcinoma. Nat Genet 2012;44:765-9. disease. N Engl J Med 2004;351:1521-31.
6. Zhang XD, Wang Y, Ye LH. Hepatitis B virus X protein accelerates 24. Zhou HY, Luo Y, Chen WD, Gong GZ. Hepatitis B virus mutation
the development of hepatoma. Cancer Biol Med 2014;11:182-90. may play a role in hepatocellular carcinoma recurrence: a systematic
7. Peng Z, Zhang Y, Gu W, Wang Z, Li D, Zhang F, Qiu G, Xie K. review and meta-regression analysis. J Gastroenterol Hepatol
Integration of the hepatitis B virus X fragment in hepatocellular 2015;30:977-83.
carcinoma and its effects on the expression of multiple molecules: a 25. Yang J, Chen X, Zhang H, Chen G. HBV genotype C strains with
key to the cell cycle and apoptosis. Int J Oncol 2005;26:467-73. spontaneous YMDD mutations may be a risk factor for hepatocellular
8. Wang HC, Huang W, Lai MD, Su IJ. Hepatitis B virus pre-S mutants, carcinoma. J Med Virol 2014;86:913-7.
endoplasmic reticulum stress and hepatocarcinogenesis. Cancer Sci 26. Yang JH, Zhang H, Chen XB, Chen G, Wang X. Relationship
2006;97:683-8. between hepatocellular carcinoma and hepatitis B virus genotype with
9. Zamarron BF, Chen W. Dual roles of immune cells and their factors in spontaneous YMDD mutations. World J Gastroenterol 2013;19:3861-
cancer development and progression. Int J Biol Sci 2011;7:651-8. 5.
10. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje 27. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R,
UH. Risk of hepatocellular carcinoma across a biological gradient of Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje
serum hepatitis B virus DNA level. JAMA 2006;295:65-73. U, Beebe S, Kreter B. Long-term entecavir therapy results in reversal
11. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past of fibrosis/cirrhosis and continued histologic improvement in chronic
HBV viral load as predictor of mortality and morbidity from HCC hepatitis B patients. Hepatology 2010;52:886-93.
and chronic liver disease in a prospective study. Am J Gastroenterol 28. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM,
2006;101:1797-803. Washington MK, Germanidis G, Flaherty JF, Schall RA, Bornstein
12. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ.
Chen PJ, Chen DS, Chen CJ. Hepatitis B e antigen and the risk of Regression of cirrhosis during treatment with tenofovir disoproxil
hepatocellular carcinoma. N Engl J Med 2002;347:168-74. fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
13. Liu D, Cui L, Wang Y, Yang G, He J, Hao R, Fan C, Qu M, Liu Lancet 2013;381:468-75.
Z, Wang M, Chen L, Li H, Guo D. Hepatitis B e antigen and its 29. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki
precursors promote the progress of hepatocellular carcinoma by H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M,
interacting with NUMB and decreasing p53 activity. Hepatology Kumada H. Long-term entecavir treatment reduces hepatocellular
2016;64:390-404. carcinoma incidence in patients with hepatitis B virus infection.
14. Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Hepatology 2013;58:98-107.
Y, Kanamori A, Kitabatake S, Yama T, Tanaka J. HBcrAg predicts 30. Kim WR, Loomba R, Berg T, Aguilar Schall RE, Yee LJ, Dinh PV,
hepatocellular carcinoma development: an analysis using time- Flaherty JF, Martins EB, Therneau TM, Jacobson I, Fung S, Gurel
dependent receiver operating characteristics. J Hepatol 2016;65:48-56. S, Buti M, Marcellin P. Impact of long-term tenofovir disoproxil
15. Seeger C, Mason WS. Molecular biology of hepatitis B virus fumarate on incidence of hepatocellular carcinoma in patients with
infection. Virology 2015;479-480:672-86. chronic hepatitis B. Cancer 2015;121:3631-8.
16. Yang Z, Zhuang L, Lu Y, Xu Q, Tang B, Chen X. Naturally occurring 31. Wu CY, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, Wu C, Wu JC.
basal core promoter A1762T/G1764A dual mutations increase the risk Association of nucleos(t)ide analogue therapy with reduced risk
of HBV-related hepatocellular carcinoma: a meta-analysis. Oncotarget of hepatocellular carcinoma in patients with chronic hepatitis B: a
2016;7:12525-36. nationwide cohort study. Gastroenterology 2014;147:143-51.e5.
17. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations 32. Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo
of hepatitis B virus increase the risk of hepatocellular carcinoma in G, Vauthey JN, Choti MA, De Santibanes E, Donadon M, Morenghi
hepatitis B carriers. Gastroenterology 2003;124:327-34. E, Makuuchi M. A snapshot of the effective indications and results of
18. Menendez-Arias L, Alvarez M, Pacheco B. Nucleoside/nucleotide surgery for hepatocellular carcinoma in tertiary referral centers: is it

290 Hepatoma Research ¦ Volume 3 ¦ November 27, 2017